Skip to main content

Testosterone

FDA recalls

9 rows

DateCompany and reasonClass
Nov 6, 2025Teva Pharmaceuticals USA, Inc
Defective Container - A defect in the side-seal which allows leakage of product.		Class III · Ongoing
Mar 4, 2025Strides Pharma, Inc.
Presence of foreign substance: Presence of Benzene.		Class II · Completed
Aug 7, 2024Teva Pharmaceuticals USA, Inc
Superpotent Drug		Class II · Ongoing
Nov 9, 2023Teva Pharmaceuticals USA, Inc
OOS for viscosity		Class III · Terminated
Jun 28, 2022Teva Pharmaceuticals USA Inc
Superpotent Drug: Out of specification assay result was obtained during stability testing.		Class II · Terminated
Nov 10, 2020Teva Pharmaceuticals USA
Superpotent Drug: High out-of-specification assay results were obtained during stability testing.		Class III · Terminated
Jun 11, 2019Invagen Pharmaceuticals, Inc.
Defective Container; actuator may improperly function and affect dose delivery.		Class III · Terminated
Mar 12, 2019Lupin Pharmaceuticals Inc.
Defective Container: Repetitive complaints received indicating pump not working.		Class III · Terminated
Oct 8, 2018Lupin Pharmaceuticals Inc.
Defective Container: Repetitive complaints received indicating pump not working.		Class III · Terminated

← Back to Testosterone

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).